PRQR -70% *ProQR Therapeutics shares are trading lower after the company reported the study did not meet the primary endpoint, nor notable secondary endpoints in the Phase 2/3 Illuminate
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.